Dalbavancin as an Option for Treatment of S. aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients with Complicated S. aureus Bacteremia


Awarded By

Total Award Amount

  • 283778.00
  • Direct Costs

  • 191097.00
  • Sponsor Award Id

  • A034260, SPS-2611113
  • Contributor

  • Breanna Bryant   Investigator  
  • Martin Rodriguez   Investigator  
  • Nathan Erdmann   Investigator  
  • Peter Pappas M.D.   Investigator  
  • Todd McCarty   Principal Investigator